Skip to main content
. 2011 Sep 9;5:93–98. doi: 10.2174/1874104501105010093

Table 5.

Pan PPAR Agonists (Ligands) and their Main Actions

Pan PPAR modulators Indication Dosage Effect Remarks
Benzafibrate (9) Type 2 diabetes mellitus, hyperlipidemia, atherosclerosis increases HDL-C level, lowers blood triglyceride and glucose levels, enhances insulin sensitivity. Marketed by Boehringer MannheimGmgH/Chong Kun Dang Pharma
Chiglitazar (10) Type 2 diabetes mellitus Currently in Phase II by Shenzhen Chipscreen Biosciences
Netoglitazone Obesity In phase II. Introduced by Mitsubishi Pharma/Perlegen Sciences